Abstract
Hannah S. Xu, Ji‐Eun Seo, Xilin Li, Nan Mei, Aisar H. Atrakchi, Karen L Davis Bruno, Sruthi Tallapragada King, Robert T. Dorsam, Naomi L. Kruhlak, Kelly Brant, Robert H. Heflich
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Nitrosamine Ames Data Review and Method Development: Proceedings of a US FDA/HESI Workshop
10.1093/mutage/geag011 · 2026
HESI GTTC Ring Trial: Concordance Between Ames and Rodent Carcinogenicity Outcomes for N‐Nitrosamines (NAs) With Rat and Hamster Metabolic Conditions
10.1016/j.yrtph.2025.105835 · 2025
Formation of N‐Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies
10.1021/acs.oprd.3c00153 · 2024
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
DNA Alkylation Damage by Nitrosamines and Relevant DNA Repair Pathways
10.3390/ijms24054684 · 2023
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Nitrosamine Acceptable Intakes Should Consider Variation in Molecular Weight: The Implication of Stoichiometric DNA Damage
10.1016/j.yrtph.2023.105505 · 2023
Ames Mutagenicity of 15 Aryl, Benzyl, and Aliphatic Ring N‐Nitrosamines
10.1016/j.yrtph.2024.105763 · 2025
Unresolved referenced work
Kept as external metadata until matched
Optimizing the Detection of N‐Nitrosamine Mutagenicity in the Ames Test
10.1016/j.yrtph.2024.105709 · 2024
Regulatory Experiences With Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals
10.1016/j.xphs.2022.12.022 · 2023
Unresolved referenced work
Kept as external metadata until matched
Measuring Reproducibility of Dose Response Data for the Pig‐a Assay Using Covariate Benchmark Dose Analysis
10.1016/j.mrgentox.2016.04.004 · 2016
Ames Concordance With the In Vivo Transgenic Rodent (TGR) Gene Mutation Assay for NDSRIs and Relative In Vivo TGR Potency With Nitrosamines With Robust Dose‐Response Carcinogenicity Data
10.1016/j.yrtph.2026.106051 · 2026
Strong Nasal Carcinogenicity and Genotoxicity of 1‐Nitroso‐4‐Methylpiperazine After Low Dose Inhalation in Rats
10.1093/carcin/20.8.1629 · 1999
Determining Recommended Acceptable Intake Limits for N‐Nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach (CPCA)
10.1016/j.yrtph.2024.105640 · 2024
Unresolved referenced work
Kept as external metadata until matched
Genotoxicity Evaluation of Nitrosamine Impurities Using Human TK6 Cells Transduced With Cytochrome P450s
10.1007/s00204-022-03347-6 · 2022
Mutagenicity and Genotoxicity Evaluation of 15 Nitrosamine Drug Substance‐Related Impurities in Human TK6 Cells
10.1016/j.yrtph.2024.105730 · 2024
Revisiting the Mutagenicity and Genotoxicity of N‐Nitroso Propranolol in Bacterial and Human In Vitro Assays
10.1016/j.yrtph.2023.105410 · 2023
Unresolved referenced work
1984
Unresolved referenced work
2017
The Nitrosamine “Saga”: Lessons Learned From Five Years of Scrutiny
10.1021/acs.oprd.3c00100 · 2023
10.1787/61eca5cd-en
10.1787/61eca5cd-en · 2017
Unresolved referenced work
Kept as external metadata until matched
Comparative DNA Damage Induced by Eight Nitrosamines in Primary Human and Macaque Hepatocytes
10.1016/j.cbi.2025.111538 · 2025
Evaluation of an In Vitro Three‐Dimensional HepaRG Spheroid Model for Genotoxicity Testing Using the High‐Throughput CometChip Platform
2022
High‐Throughput Micronucleus Assay Using Three‐Dimensional HepaRG Spheroids for In Vitro Genotoxicity Testing
10.1007/s00204-023-03461-z · 2023
Quantitative Comparison of In Vitro Genotoxicity Between Metabolically Competent HepaRG Cells and HepG2 Cells Using the High‐Throughput High‐Content CometChip Assay
10.1007/s00204-019-02406-9 · 2019
Genotoxicity Evaluation of Ten Nitrosamine Drug Substance‐Related Impurities Using 2D and 3D HepaRG Cell Models
10.1016/j.yrtph.2025.105906 · 2025
Genotoxicity Assessment of Eight Nitrosamines Using 2D and 3D HepaRG Cell Models
10.1007/s00204-023-03560-x · 2023
Bumetanide as a Model NDSRI Substrate: N‐Nitrosobumetanide Impurity Formation and Its Inhibition in Bumetanide Tablets
10.1016/j.xphs.2023.06.013 · 2023
Unresolved referenced work
Kept as external metadata until matched
N‐Nitroso‐Phenylephrine, a Nitrosamine Drug Substance‐Related Impurity That Is Negative in the Enhanced Ames Test but Mutagenic in HepaRG Cells
2026
No additional external references are available.